Quick Answer
NewAmsterdam Pharma Co N.V. reported Stockholders Equity of $683.43 million for fiscal year 2025.
NewAmsterdam Pharma Co N.V. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $683.43M | -9.8% |
| 2024 | $757.50M | +162.7% |
| 2023 | $288.39M | -32.9% |
| 2022 | $430.07M | +477.9% |
| 2021 | -$113.82M | -55.8% |
| 2020 | -$73.03M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $728.07M | +92.2% | -6.5% |
| June 30, 2025 | $778.50M | +100.9% | +0.1% |
| March 31, 2025 | $777.36M | +88.8% | +2.6% |
| December 31, 2024 | $757.50M | +162.7% | +99.9% |
| September 30, 2024 | $378.86M | +14.2% | -2.2% |
| June 30, 2024 | $387.44M | +3.8% | -5.9% |
| March 31, 2024 | $411.80M | +3.4% | +42.8% |
| December 31, 2023 | $288.39M | -32.9% | -13.1% |
- NewAmsterdam Pharma Co N.V. showed a decrease of -9.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, NewAmsterdam Pharma Co N.V.’s stockholders equity has grown by 1035.8% (from -$73.03 million to $683.43 million).
- The most recent figure is from NewAmsterdam Pharma Co N.V.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: